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Reply
We thank Dr. Jeong and colleagues for their comments with
regard to our study (1). We well know that previous studies
investigated on-clopidogrel platelet reactivity (PR) through
follow-up (2,3). Nevertheless, these findings were observations in
studies planned for other aims. Our study is the first investigating
the incidence of clopidogrel poor response at baseline versus that at
1 month as the primary endpoint and assessing the different
influence over time of genetic and environmental PR determi-
nants. Principally, 3 points were raised: the first concerns the
timing of measurements with respect to the last dose administra-
tion, the second refers to the occurrence of adverse events, and the
third touches on the independent determinants of bleeding.
Firstly, in our study, the maintenance dose of clopidogrel was
taken in the morning, and the blood sample to evaluate PR was
collected 1 to 5 h later. Considering both the time between drug
intake and blood sample and the degree of platelet reactivity
(PRU) value variation between “acute” and “chronic” phases, we
believe that the potential influence related to timing of measure-
ment may be minimal. Secondly, one of our aims was to assess the
predictive role of 1 month PRU value as compared to baselinevalue. So, as clearly reported in the Methods section, clinical events
that occurred after 1 month and up to 1 year of follow-up were
deliberately considered for this purpose. Patients with adverse
events during the first month were excluded. Third, it is plausible
that CYP2C19*17 carriership indicates a “chronic” tendency to
have lower PRU values. Nevertheless, other environmental factors
may still influence PRU values irrespective of *17 carriership. This
aspect could explain partially why both CYP2C19*17 and PRU
values emerged as independent predictors of bleeding complica-
tions. This observation is intriguing and deserves further investi-
gation, as it alone would strongly reinforce the concept that both
phenotype and genotype should integrate the clinical decision
making about the more appropriate choice of oral P2Y12 inhibitor.
Therefore, we agree with Dr. Jeong and colleagues when they
affirmed that, in the future, comprehensive algorithms including
clinical, genetic, and laboratory findings are needed to permit us to
optimize antiplatelet therapy in each individual patient. Our study
is one of the first efforts in this direction, and the value of
integrating this working algorithm into clinical practice versus a
purely clinically driven choice of P2Y12 inhibitor is currently being
tested as a pre-specified substudy of the MATRIX (Minimizing
Adverse Haemmhorragic Events by Transradial Access Site and
Systemic Implementation of Angiox) study.
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